KangLaiTe-USA has reported promising preliminary findings of the U.S. Phase II clinical trial studying its leading investigational drug Kanglaite Injection in pancreatic cancer.
KangLaiTe’s lead investigational drug Kanglaite Injection (KLTi) is sourced from the natural seeds of the Coixlacryma-jobi plant, or Job’s tears, which has been used in traditional Chinese medicine for thousands of years. KLTi is now used in countries throughout the world to treat various cancers and cancer symptoms.
Western clinical oncology focuses on attacking malignant tumors as aggressively as possible, with side effects of the anti-cancer drugs sometimes being significant. In the later stages of cancer, the primary treatment focus typically shifts to quality of life, pain management, and an emphasis on nutrition. In China, physicians initially focus on quality of life, the ability to perform the tasks of daily living, pain management, and control of nausea, vomiting, and other symptoms. Once the patient is more comfortable and stable, the malignant tumor is attacked in the same way it is in the West, using the same methods and medications.
It is in this context, focusing on the symptoms first, that Kanglaite Injection was originally developed in China. The drug was developed from a food grain, Coixlacryma-jobi, or Job’s tears, whose therapeutic benefits were originally described thousands of years ago in traditional Chinese medicine. The drug that was developed from this grain is approved in China and used both in patients critically ill with newly discovered cancer and in patients who are near the end of their course of treatment and need palliative care. In each case, the drug is reported to reduce signs and symptoms associated with cancer, such as anorexia (no appetite), cachexia (progressive weight loss with muscle wasting), and pain while still shrinking tumors. The drug is used as sole therapy and in combination with chemotherapy.
Clinical Trial of Kanglaite Injection (KLTi) for Pancreatic Cancer
KangLaiTe-USA is studying pancreatic cancer as the first potential treatment focus for its lead investigational drug candidate. A phase II clinical trial of Kanglaite Injection in advanced pancreatic cancer patients to compare KLTi + Gemcitabine with Gemcitabine monotherapy was completed in 2014 with significant benefits in progression-free survival (PFS), overall survival (OS) and objective response rate observed in patients receiving KLTi + Gemcitabin.
Clinical Trial of Kanglaite Gel Cap (KLTc) for Prostate Cancer
KangLaiTe USA has completed a phase II clinical trial for Kanglaite gel cap in prostate cancer patients. The purpose of the trial was to study the effect KLTc has on prostate specific antigen doubling time (PSADT) in men who have a rising PSA after initial therapy for localized prostate cancer.
For More Information
KangLaiTe-USA posts information for all ongoing clinical trials on the National Institutes of Health’s (NIH) clinicaltrials.gov website.
Please refer to the list of studies in the Clinical Trials section of this web site for more information. KLTi is not available at this time outside of an FDA-approved protocol, and no compassionate use protocols are currently available.